open access

Vol 24, No 1 (2019)
Original research articles
Published online: 2019-01-01
Submitted: 2017-07-18
Get Citation

Survival after radiation therapy for high-grade glioma

Joana Spaggiari Marra, Guilherme Paulão Mendes, Gerson Hiroshi Yoshinari, Flávio da Silva Guimarães, Suleimy Cristina Mazin, Harley Francisco de Oliveira
DOI: 10.1016/j.rpor.2018.09.003
·
Rep Pract Oncol Radiother 2019;24(1):35-40.

open access

Vol 24, No 1 (2019)
Original research articles
Published online: 2019-01-01
Submitted: 2017-07-18

Abstract

Background

High-grade gliomas (HGGs) are a heterogeneous disease group, with variable prognosis, inevitably causing deterioration of the quality of life. The estimated 2-year overall survival is 20%, despite the best trimodality treatment consisting of surgery, chemotherapy, and radiotherapy.

Aim

To evaluate long-term survival outcomes and factors influencing the survival of patients with high-grade gliomas treated with radiotherapy.

Materials and methods

Data from 47 patients diagnosed with high-grade gliomas between 2009 and 2014 and treated with three-dimensional radiotherapy (3DRT) or intensity-modulated radiotherapy (IMRT) were analyzed retrospectively.

Results

Median survival was 16.6 months; 29 patients (62%) died before the time of analysis. IMRT was employed in 68% of cases. The mean duration of radiotherapy was 56 days, and the mean delay to the start of radiotherapy was 61.7 days (range, 27–123 days). There were no statistically significant effects of duration of radiotherapy or delay to the start of radiotherapy on patient outcomes.

Conclusions

Age, total amount of gross resection, histological type, and use of adjuvant temozolomide influenced survival rate (p<0.05). The estimated overall survival was 18 months (Kaplan–Meier estimator). Our results corroborated those reported in the literature.

Abstract

Background

High-grade gliomas (HGGs) are a heterogeneous disease group, with variable prognosis, inevitably causing deterioration of the quality of life. The estimated 2-year overall survival is 20%, despite the best trimodality treatment consisting of surgery, chemotherapy, and radiotherapy.

Aim

To evaluate long-term survival outcomes and factors influencing the survival of patients with high-grade gliomas treated with radiotherapy.

Materials and methods

Data from 47 patients diagnosed with high-grade gliomas between 2009 and 2014 and treated with three-dimensional radiotherapy (3DRT) or intensity-modulated radiotherapy (IMRT) were analyzed retrospectively.

Results

Median survival was 16.6 months; 29 patients (62%) died before the time of analysis. IMRT was employed in 68% of cases. The mean duration of radiotherapy was 56 days, and the mean delay to the start of radiotherapy was 61.7 days (range, 27–123 days). There were no statistically significant effects of duration of radiotherapy or delay to the start of radiotherapy on patient outcomes.

Conclusions

Age, total amount of gross resection, histological type, and use of adjuvant temozolomide influenced survival rate (p<0.05). The estimated overall survival was 18 months (Kaplan–Meier estimator). Our results corroborated those reported in the literature.

Get Citation

Keywords

Radiotherapy; Anaplastic; Glioma; Chemotherapy; Glioblastoma

About this article
Title

Survival after radiation therapy for high-grade glioma

Journal

Reports of Practical Oncology and Radiotherapy

Issue

Vol 24, No 1 (2019)

Pages

35-40

Published online

2019-01-01

DOI

10.1016/j.rpor.2018.09.003

Bibliographic record

Rep Pract Oncol Radiother 2019;24(1):35-40.

Keywords

Radiotherapy
Anaplastic
Glioma
Chemotherapy
Glioblastoma

Authors

Joana Spaggiari Marra
Guilherme Paulão Mendes
Gerson Hiroshi Yoshinari
Flávio da Silva Guimarães
Suleimy Cristina Mazin
Harley Francisco de Oliveira

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl